These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder. Foster RH; Goa KL CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224 [TBL] [Abstract][Full Text] [Related]
3. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Preskorn SH Clin Pharmacokinet; 1997; 32 Suppl 1():1-21. PubMed ID: 9068931 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Baumann P Clin Pharmacokinet; 1996 Dec; 31(6):444-69. PubMed ID: 8968657 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Sánchez C; Hyttel J Cell Mol Neurobiol; 1999 Aug; 19(4):467-89. PubMed ID: 10379421 [TBL] [Abstract][Full Text] [Related]
15. Overview of the pharmacokinetics of fluvoxamine. van Harten J Clin Pharmacokinet; 1995; 29 Suppl 1():1-9. PubMed ID: 8846617 [TBL] [Abstract][Full Text] [Related]
16. Care of depression in the elderly: comparative pharmacokinetics of SSRIs. Baumann P Int Clin Psychopharmacol; 1998 Sep; 13 Suppl 5():S35-43. PubMed ID: 9817619 [TBL] [Abstract][Full Text] [Related]
18. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Edwards JG; Anderson I Drugs; 1999 Apr; 57(4):507-33. PubMed ID: 10235690 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the effects of the selective serotonin-reuptake inhibitors fluoxetine, paroxetine, citalopram and fluvoxamine in alcohol-preferring cAA rats. Maurel S; De Vry J; Schreiber R Alcohol; 1999 Apr; 17(3):195-201. PubMed ID: 10231167 [TBL] [Abstract][Full Text] [Related]
20. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Rasmussen BB; Brøsen K Ther Drug Monit; 2000 Apr; 22(2):143-54. PubMed ID: 10774624 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]